# Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab

> **NCT05928897** · PHASE2 · UNKNOWN · sponsor: **Xiangya Hospital of Central South University** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Disitamab Vedotin combined with Sintilimab

## Key facts

- **NCT ID:** NCT05928897
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05928897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05928897, "Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05928897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*